What will attenuate that inequity is not stretching current stocks further. No one seriously believes that if we had say 40% more available Moderna vaccine, that *any* of it would end up in lower-income countries.
Yes. And also, again, without judgment on the outcome of this question, there have been a bunch of curveballs from trials that prior knowledge did not predict. Efficacy of mRNA vaccines. Dexamethasone (many thought it would not work and would harm) that emerged from UK/RECOVERY.
-
-
Ideally, UK would do this as if it were an adaptive trial: with transparency and a means to halt/reverse (especially for those at high risk for severe disease). Or do a tiered approach: emphasize booster for elderly while watching younger cohorts. Etc.
-
I think trade-offs and some kitchen-sinking is inevitable, and ideally we'd approach this with "how do we resolve this as fast as possible, while maintaining public trust" kind of approach. To me, that's always randomize when/if possible, collect data always.
- Show replies
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.